Literature DB >> 8225685

Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population.

J C Duché1, V Quérol-Ferrer, J Barré, M Mésangeau, J P Tillement.   

Abstract

The dextromethorphan (DMP) O-demethylation and the dextrorphan (DRP) glucuronidation distributions were studied in 120 French Caucasian subjects. After a single 25 mg DMP oral administration, DMP, free and total DRP concentrations were measured in 8h-urine collection, using an HPLC technique with fluorescent detection. The DMP and free DRP concentrations ratio, in log form, was used to estimate the oxidative demethylation phenotype of the subjects. Two different populations were found. The first one consisted of the extensive metabolizers (90.8%, 95% confidence interval from 85.6 to 95.9%) and the second one consisted of poor metabolizers (9.2%, 95% confidence interval from 4.0 to 14.4%). The antimode value of the distribution was estimated at approximately 0.7 corresponding to a ratio of 5. Moreover, this ratio was compared to the DMP and total DRP concentrations ratio, usually defined to DMP O-demethylation phenotyping. On the other hand, the glucuronide DRP concentration was calculated by subtracting the free DRP concentration from the total DRP concentration. Consequently, the free DRP and glucuronide DRP concentrations ratio was also used to estimate the DRP glucuronidation in the present population. This ratio in log form reflected the UDP-glucuronyltransferase(s) capacity(ies). This log ratio appeared to be normally distributed in the population studied. These results show that log DMP/free DRP ratio can be used, as well as log DMP/total DRP ratio, to determine the oxidative phenotype of subjects and that the DRP conjugation does not exhibit any apparent genetic polymorphism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225685

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  6 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 2.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

3.  Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.

Authors:  Justin D Lutz; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

4.  Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers.

Authors:  G P Pageaux; J Micallef; M B Nataf; J C Levron; B Lacarelle; J P Le Moing; P Bouhours; O Blin
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 5.  Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

Authors:  B Burchell; M W Coughtrie
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

6.  CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D610 on Interindividual Variation in a Chinese Population.

Authors:  Rui Chen; Xin Zheng; Pei Hu
Journal:  Front Pharmacol       Date:  2017-05-02       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.